

<Page>

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 4, 2004

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

22-0760120

(Commission File Number)

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

07417-1880

(Address of Principal Executive Offices)

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

<Page>

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2004, Becton, Dickinson and Company issued a press release announcing its financial results for the fourth fiscal quarter and for the fiscal year ended September 30, 2004. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits.

Exhibit 99.1 Press release dated November 4, 2004, which is furnished pursuant to Item 2.02.

<Page>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Dean J. Paranicas

Dean J. Paranicas
Vice President, Corporate
Secretary and Public Policy

Date: November 4, 2004

<Page>

INDEX TO EXHIBITS

Exhibit Number -----	Description of Exhibits -----
99.1	Press release dated November 4, 2004, which is furnished pursuant to Item 2.02.

STATEMENT OF DIFFERENCES

The trademark symbol shall be expressed as.....'TM'

<Page>

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com

[BECTON DICKINSON LOGO]

Contact:

- -----
Patricia A. Spinella, Investor Relations - 201-847-5453
Colleen T. White, Corporate Communications - 201-847-5369

BD ANNOUNCES FISCAL FOURTH QUARTER
AND FULL YEAR RESULTS

Franklin Lakes, NJ (November 4, 2004) - BD (Becton, Dickinson and Company) (NYSE: BDX) today reported quarterly revenues from continuing operations of \$1.253 billion for the fiscal fourth quarter ended September 30, 2004, representing an increase of 8 percent from the same period a year ago. For the full year, the Company reported record revenues of \$4.935 billion from continuing operations, which represents an 11 percent increase over the same period a year ago. At constant foreign exchange rates, revenues increased 5 percent for the quarter and 6 percent for the fiscal year. Revenue growth in all segments benefited from favorable foreign currency translation, particularly with respect to the Euro, for the quarter and the year.

"We had a strong finish to a successful year in which BD exceeded its operating goals and showed significant improvement over 2003," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "In the fourth quarter, all segments contributed solid revenue growth, resulting in diluted earnings per share from continuing operations of 70 cents, which exceeded our expectations. For the year, pro forma gross profit margin improvement of 100 basis points and cash flow from operations of over \$1 billion were driven by a combination of revenue growth, continued operating effectiveness and productivity improvement."

Reported diluted earnings per share for the fourth quarter were 26 cents, which reflected diluted earnings per share of 70 cents from continuing operations, and a loss of 44 cents per share from discontinued operations. Reported diluted earnings per share for the year were \$1.77, which reflected diluted earnings per share of \$2.21 from continuing operations, and a loss of 44 cents per share from discontinued operations. Included in the results of continuing operations for the year were a first quarter charge of 11 cents related to our blood glucose monitoring products and a third quarter charge of 24 cents related to the settlement of the Retractable Technologies, Inc. litigation. Excluding these items, pro forma diluted earnings per share from continuing operations for fiscal 2004 were \$2.56.

Reconciliations of these pro forma financial measures and other financial measures discussed in this release are provided in the tables below.

<Page>

Planned Sale of Clontech Operation

On October 4, 2004, BD announced that a plan had been initiated to offer Clontech, a unit of the BD Biosciences segment, for sale. The results of operations for Clontech have been classified as "discontinued operations" for all quarters and years referred to in this release. In connection with the planned disposition, BD has recorded a charge in the fourth quarter of 44 cents per diluted share in the results of discontinued operations, reflecting the write-down of Clontech's net assets to estimated fair value. Also included in the results of discontinued operations for the quarter and the year were a loss from operations of \$0.1 million and income from operations of \$0.7 million, respectively, resulting in an impact of less than 1 cent on reported diluted earnings per share for the quarter and the year.

Fourth Quarter and Full Year 2003

Reported diluted earnings per share for the fourth quarter of fiscal year 2003 were 61 cents, which included a net loss from discontinued operations of \$0.9 million (less than 1 cent diluted earnings per share).

Reported diluted earnings per share for fiscal year 2003 were \$2.07 and reflected diluted earnings per share of \$2.10 from continuing operations and a

loss of 3 cents per share from discontinued operations. The loss from discontinued operations included 2 cents per diluted share related to the write-down of certain intangible assets and inventory and 1 cent per diluted share of operating loss. Also reflected in the full fiscal year 2003 diluted earnings per share from continuing operations were additional charges of 6 cents per diluted share related to the write-down of certain intangible assets and inventory in the BD Biosciences segment unrelated to Clontech. Excluding this 6 cents charge per diluted share, pro forma diluted earnings per share from continuing operations for fiscal 2003 were \$2.16.

Reconciliations of Reported Results

The following tables are provided to assist in reconciling reported diluted earnings per share to diluted earnings per share from continuing operations and pro forma diluted earnings per share from continuing operations:

<Page>

Reconciliation from Reported Diluted Earnings Per Share to Diluted Earnings Per Share from Continuing Operations and Pro Forma Diluted Earnings Per Share from Continuing Operations

<TABLE>
<CAPTION>

	2004 -----	2003 -----	% Growth -----
<S>	<C>	<C>	<C>
Three Months Ended September 30, Reported Diluted EPS:	\$ 0.26 -----	\$0.61 -----	
Diluted EPS from Discontinued Operations:			
Loss from Discontinued Operations	0.00 (1)	0.00 (2)	
Write-down of Clontech Net Assets	0.44	--	
	----- 0.44	----- 0.00	
Diluted EPS from Continuing Operations	\$ 0.70 =====	\$ 0.62 (2) =====	13% =====

</TABLE>

(1) Loss from FY2004 Discontinued Operations of \$(0.1) Million is less than \$(0.01) Diluted EPS.

(2) Loss from FY2003 Discontinued Operations of \$(0.9) Million is less than \$(0.01) Diluted EPS, however, due to rounding, Diluted EPS from Continuing Operations is \$0.01 higher than Reported Diluted EPS.

<TABLE>
<CAPTION>

Full Year:

	<C>	<C>	
<S>	<C>	<C>	
Reported Diluted EPS:	\$ 1.77 -----	\$ 2.07 -----	
Diluted EPS from Discontinued Operations:			
(Income)/Loss from Discontinued Operations (3)	(0.00)	0.01	
Write-down of Clontech Net Assets	0.44	--	
Non-cash charges	--	0.02 (4)	
	----- 0.44	----- 0.03	
Diluted EPS from Continuing Operations	2.21 -----	2.10 -----	
Pro Forma Adjustments:			
BGM Charges	0.11	--	
Litigation Settlement	0.24	--	
Non-cash charges	--	0.06 (4)	
	----- 0.35	----- 0.06	
Pro Forma Diluted EPS from Continuing Operations	\$ 2.56 =====	\$ 2.16 =====	19% =====

</TABLE>

- (3) Income from FY2004 Discontinued Operations of \$0.7 Million is less than \$0.01 Diluted EPS. Loss from FY2003 Discontinued Operations of \$(3.8) Million represents \$0.01 Diluted EPS.
- (4) Total of \$0.08 relates to charges in the third quarter of FY2003, reflecting write-down of certain intangible assets and inventory in the BD Biosciences segment, of which \$0.02 is related to Clontech.

<Page>

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$688 million, representing an increase of 8 percent over the prior year period. BD Medical revenues reflect the continued conversion in the U.S. to safety-engineered products, accounting for sales of \$118 million compared with \$108 million in the prior year's quarter. Also contributing to the growth of the segment were sales of prefillable drug delivery devices, which grew to \$126 million from \$101 million in the prior year's quarter. U.S. sales of safety-engineered products for the full year in the BD Medical segment totaled \$448 million compared with \$407 million in the prior year. BD Medical worldwide revenues for the year were \$2.680 billion, representing an increase of 9 percent over the prior year.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$374 million, representing an increase of 8 percent over the prior year period. Revenue growth of 12 percent in the Preanalytical Systems unit of the segment reflects the continued conversion in the U.S. to safety-engineered products, accounting for sales of \$85 million, compared with \$74 million in the prior year's quarter. U.S. sales of safety-engineered products for the full year in the BD Diagnostics segment totaled \$317 million compared with \$273 million in the prior year. Total U.S. sales of safety-engineered products for the full year were \$765 million compared with \$680 million in the prior year, representing an increase of 13 percent. Revenue growth in the Diagnostic Systems unit of the segment was 3 percent for the quarter. Sales of the unit's molecular diagnostic platform, the BD ProbeTec™ ET system, continued to contribute to its growth, while sales of respiratory and flu diagnostic tests for the quarter were lower than the prior year's period due to a shift in the timing of distributor purchases, which are expected to occur over the next two quarters. In the BD Diagnostics segment, worldwide revenues for the full fiscal year were \$1.532 billion, representing an increase of 12 percent over the prior year.

In the BD Biosciences segment, worldwide revenues from continuing operations for the quarter were \$192 million, representing an increase of 7 percent over the prior year period. Instrument revenue growth was driven by sales of the recently launched BD FACSCanto™ and BD FACSAria™ analyzers and continued strong market acceptance of the BD FACSAria™ cell sorter. Fourth quarter sales of flow cytometry reagents were also strong in both the clinical and research markets. BD Biosciences worldwide revenues for the year were \$723 million, representing an increase of 14 percent over the prior year. As previously discussed, revenue results exclude sales from the Clontech business unit.

Geographic Results

Fourth quarter revenues in the U.S. of \$631 million represented an increase of 5 percent over the prior year period. Revenues outside the U.S. of \$622 million represented an increase of 11 percent over the prior year period, or 6 percent at constant foreign exchange rates. For the full year, revenues in the U.S. of \$2.436 billion represented an increase of 6 percent over the prior year. Revenues outside the U.S. of \$2.499 billion increased by 15 percent, or 6 percent at constant foreign exchange rates.

Fiscal 2005 Outlook

The Company estimates pro forma diluted earnings per share from continuing operations for fiscal 2005 will increase in the range of 10 to 12 percent as compared with fiscal 2004 pro forma diluted earnings per share from continuing operations of \$2.56, excluding the anticipated impact of expensing equity-based compensation as described below.

<Page>

The Company also estimates that first quarter 2005 pro forma diluted earnings

per share from continuing operations will increase about 7 percent, compared with fiscal first quarter 2004 pro forma diluted earnings per share from continuing operations of 58 cents, which excludes the previously noted charge of 11 cents per diluted share related to our blood glucose monitoring products. Anticipated first quarter growth is affected by the timing of respiratory and flu diagnostic sales, which occurred in the fiscal first quarter of last year due to an early expectation of an unusually severe flu season.

Equity-Based Compensation

The Company anticipates that it will adopt, in the first quarter of fiscal 2005, the fair value recognition provisions for stock-based compensation in accordance with Statement of Financial Accounting Standards (SFAS) No. 123, "Accounting for Stock-Based Compensation," as amended by SFAS No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure." As a result, prior unvested stock options and new equity-based awards issued pursuant to the Company's previously approved long-term incentive program (which replaces, in part, grants of stock options with performance-based stock awards and restricted stock units), will begin to be expensed. These changes, in the aggregate, are estimated to reduce full year fiscal 2005 pro forma diluted earnings per share from continuing operations by about 6 percent.

Conference Call Information

A conference call regarding BD's fourth quarter and full year results and expectations for fiscal 2005 will be broadcast live on BD's website (www.bd.com/investors) at 10:00 a.m. (ET) Thursday, November 4, 2004. A replay of the conference call will be available on the investors page of BD's website or at 1-800-685-8573 (domestic) and 1-402-220-0286 (international) through Thursday, November 11, 2004.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in the news release and in the attached financial tables.

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. For the fiscal year ended September 30, 2004, BD reported revenues of \$4.935 billion.

This press release, including the section entitled "Fiscal 2005 Outlook," contains certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to statements regarding the charge BD recorded in the fourth quarter of fiscal 2004, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: BD's ability to successfully complete the proposed divestiture within the expected time frame; and the structure of any transaction involving a divestiture of Clontech and the purchase price and other terms relating thereto. With respect to other forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign

<Page>

currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

<Page>

TO BUSINESS EDITOR:

Page 1

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	Three Months Ended September 30,		
	2004	2003 (restated)	% Change
<S>	<C>	<C>	<C>
REVENUES	\$1,253,278	\$1,161,377	7.9
Cost of products sold	620,978	577,605	7.5
Selling and administrative	320,269	309,585	3.5
Research and development	58,708	52,460	11.9
TOTAL OPERATING COSTS AND EXPENSES	999,955	939,650	6.4
OPERATING INCOME	253,323	221,727	14.2
Interest expense, net	(8,592)	(9,614)	(10.6)
Other (expense) income, net	(161)	948	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	244,570	213,061	14.8
Income tax provision	61,236	50,800	20.5
INCOME FROM CONTINUING OPERATIONS	183,334	162,261	13.0
LOSS FROM DISCONTINUED OPERATIONS NET OF INCOME TAXES OF \$8,349 IN 2004 AND \$540 IN 2003, RESPECTIVELY	(115,890)	(901)	NM
NET INCOME	\$ 67,444	\$ 161,360	(58.2)
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$0.73	\$0.64	14.1
Loss from discontinued operations	\$(0.46)	\$ -	NM
Net income	\$0.27	\$0.64	(57.8)
Diluted:			
Income from continuing operations	\$0.70	\$0.62	12.9
Loss from discontinued operations	\$(0.44)	\$ -	NM
Net income	\$0.26	\$0.61	(57.4)
AVERAGE SHARES OUTSTANDING			
Basic	250,202	252,983	
Diluted	261,334	262,601	

NM - Not Meaningful

</TABLE>

<Page>

Page 2

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

Twelve Months Ended September 30,
2004 2003 (restated) % Change

<S>	<C>	<C>	<C>
REVENUES	\$4,934,745	\$4,463,509	10.6
Cost of products sold	2,500,362*	2,296,637**	8.9
Selling and administrative	1,311,467	1,181,403	11.0
Research and development	235,649	224,237	5.1
Litigation settlement	100,000	-	NM
TOTAL OPERATING COSTS AND EXPENSES	4,147,478	3,702,277	12.0
OPERATING INCOME	787,267	761,232	3.4
Interest expense, net	(29,607)	(36,549)	(19.0)
Other (expense) income, net	(4,792)	(2,725)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	752,868	721,958	4.3
Income tax provision	170,364	167,028	2.0
INCOME FROM CONTINUING OPERATIONS	582,504	554,930	5.0
LOSS FROM DISCONTINUED OPERATIONS NET OF INCOME TAXES OF \$7,961 IN 2004 AND \$4,378 IN 2003, RESPECTIVELY	(115,102)	(7,874)	NM
NET INCOME	\$467,402	\$547,056	(14.6)
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$2.30	\$2.17	6.0
Loss from discontinued operations	\$(0.46)	\$(0.03)	NM
Net income	\$1.85	\$2.14	(13.6)
Diluted:			
Income from continuing operations	\$2.21	\$2.10	5.2
Loss from discontinued operations	\$(0.44)	\$(0.03)	NM
Net income	\$1.77	\$2.07	(14.5)
AVERAGE SHARES OUTSTANDING			
Basic	252,011	254,497	
Diluted**	263,337	263,635	

NM - Not Meaningful

</TABLE>

* Includes a \$45,024 charge associated with blood glucose monitoring (BGM) products.

**Includes \$27,257 of non-cash charges, as more fully described on page 3.

<Page>

Page 3

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Periods Ended September 30,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	2004			
	As Reported	BGM Charges*	Litigation Settlement**	Excluding Charges
<S>	<C>	<C>	<C>	<C>
Gross Profit	\$2,434,383	\$45,024	\$ -	\$2,479,407
as a % of revenues	49.3%			50.2%
Operating Income	\$ 787,267	\$45,024	\$100,000	\$ 932,291
as a % of revenues	16.0%			18.9%

Income from Continuing Operations as a % of revenues	\$ 582,504 11.8%	\$27,915	\$ 63,000	\$ 673,419 13.6%
--	---------------------	----------	-----------	---------------------

</TABLE>

<TABLE>
<CAPTION>

2003 (restated)

	As Reported	Non-cash Charges***	Excluding Charges
<S>	<C>	<C>	<C>
Gross Profit as a % of revenues	\$2,166,872 48.5%	\$27,257	\$2,194,129 49.2%
Operating Income as a % of revenues	\$ 761,232 17.1%	\$27,257	\$ 788,489 17.7%
Income from Continuing Operations as a % of revenues	\$ 554,930 12.4%	\$16,082	\$ 571,012 12.8%

</TABLE>

- * Relates to the fiscal 2004 charge associated with blood glucose monitoring (BGM) products.
- ** Relates to the fiscal 2004 charge associated with the settlement of litigation with Retractable Technologies, Inc.
- *** Relates to the fiscal 2003 write-down of certain intangible assets and inventory in the BD Biosciences segment.

BECTON DICKINSON AND COMPANY
DISCONTINUED OPERATIONS SUPPLEMENTAL INFORMATION
Periods Ended September 30,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

Twelve Months Ended September 30,

	2004	2003	% Change
<S>	<C>	<C>	<C>
Revenues	\$60,513	\$64,431	(6.1)

</TABLE>

BECTON DICKINSON AND COMPANY
RECONCILIATION TO PRO FORMA AMOUNTS
THREE MONTHS ENDED DECEMBER 31,
(Unaudited)

<TABLE>
<CAPTION>

2003 (restated)

	As Reported*	BGM Charges**	Excluding Charges
<S>	<C>	<C>	<C>
Diluted EPS from continuing operations	\$0.48	\$0.11	\$0.58

</TABLE>

- * Includes income from discontinued operations of \$0.5 million which amounts to less than \$0.01 of diluted EPS from continuing operations.
- **Relates to the fiscal 2004 charge associated with blood glucose monitoring (BGM) products.

<Page>

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION (FROM CONTINUING OPERATIONS)
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

<S>	Three Months Ended September 30,		
	2004	2003 (restated)	% Change
<C>	<C>	<C>	<C>
BD MEDICAL			
United States	\$ 334,189	\$ 316,701	5.5
International	353,822	318,291	11.2
TOTAL	\$ 688,011	\$ 634,992	8.3
BD DIAGNOSTICS			
United States	\$ 207,979	\$ 197,111	5.5
International	165,645	149,903	10.5
TOTAL	\$ 373,624	\$ 347,014	7.7
BD BIOSCIENCES			
United States	\$ 89,157	\$ 88,931	0.3
International	102,486	90,440	13.3
TOTAL	\$ 191,643	\$ 179,371	6.8
TOTAL REVENUES			
United States	\$ 631,325	\$ 602,743	4.7
International	621,953	558,634	11.3
TOTAL	\$1,253,278	\$1,161,377	7.9

</TABLE>

<Page>

Page 5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION (FROM CONTINUING OPERATIONS)
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

<S>	Twelve Months Ended September 30,		
	2004	2003 (restated)	% Change
<C>	<C>	<C>	<C>
BD MEDICAL			
United States	\$1,274,936	\$1,211,957	5.2
International	1,405,229	1,244,919	12.9
TOTAL	\$2,680,165	\$2,456,876	9.1
BD DIAGNOSTICS			
United States	\$ 839,157	\$ 785,737	6.8
International	692,482	587,914	17.8
TOTAL	\$1,531,639	\$1,373,651	11.5
BD BIOSCIENCES			
United States	\$ 321,796	\$ 298,624	7.8
International	401,145	334,358	20.0
TOTAL	\$ 722,941	\$ 632,982	14.2
TOTAL REVENUES			
United States	\$2,435,889	\$2,296,318	6.1
International	2,498,856	2,167,191	15.3
TOTAL	\$4,934,745	\$4,463,509	10.6

</TABLE>

<Page>

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION (FROM CONTINUING OPERATIONS)
 REVENUES BY BUSINESS SEGMENTS AND UNITS
 Three Months Ended September 30,
 (Unaudited; Amounts in thousands)

<TABLE>
 <CAPTION>

<S>	United States		
	2004 <C>	2003 (restated) <C>	% Change <C>
BD MEDICAL			
Medical Surgical Systems	\$208,185	\$195,314	6.6
Diabetes Care	91,397	95,129	(3.9)
Pharmaceutical Systems	29,014	21,071	37.7
Ophthalmic Systems	5,593	5,187	7.8
TOTAL	\$334,189	\$316,701	5.5
BD DIAGNOSTICS			
Preanalytical Systems	\$117,624	\$107,420	9.5
Diagnostic Systems	90,355	89,691	0.7
TOTAL	\$207,979	\$197,111	5.5
BD BIOSCIENCES			
Discovery Labware	\$ 26,588	\$ 26,210	1.4
Immunocytometry Systems	43,973	44,722	(1.7)
Pharmingén	18,596	17,999	3.3
TOTAL	\$ 89,157	\$ 88,931	0.3
TOTAL UNITED STATES	\$631,325	\$602,743	4.7

</TABLE>

<Page>

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION (FROM CONTINUING OPERATIONS)
 REVENUES BY BUSINESS SEGMENTS AND UNITS
 Three Months Ended September 30, (continued)
 (Unaudited; Amounts in thousands)

<TABLE>
 <CAPTION>

<S>	International				
	2004 <C>	2003 (restated) <C>	% Change		
			Reported <C>	FX Neutral <C>	FX Impact <C>
BD MEDICAL					
Medical Surgical Systems	\$184,984	\$173,597	6.6	2.7	3.9
Diabetes Care	63,707	56,707	12.3	6.3	6.0
Pharmaceutical Systems	96,621	80,154	20.5	13.8	6.7
Ophthalmic Systems	8,510	7,833	8.6	1.5	7.1
TOTAL	\$353,822	\$318,291	11.2	6.1	5.1
BD DIAGNOSTICS					
Preanalytical Systems	\$ 87,504	\$ 76,027	15.1	9.3	5.8
Diagnostic Systems	78,141	73,876	5.8	0.8	5.0
TOTAL	\$165,645	\$149,903	10.5	5.1	5.4
BD BIOSCIENCES					
Discovery Labware	\$ 22,366	\$ 21,303	5.0	(1.0)	6.0
Immunocytometry Systems	65,631	56,123	16.9	10.1	6.8
Pharmingén	14,489	13,014	11.3	4.7	6.6
TOTAL	\$102,486	\$ 90,440	13.3	6.7	6.6
TOTAL INTERNATIONAL	\$621,953	\$558,634	11.3	5.9	5.4

</TABLE>

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION (FROM CONTINUING OPERATIONS)
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

<S>	Total		% Change <C>	FX Neutral <C>	FX Impact <C>
	2004 <C>	2003 (restated) <C>			
BD MEDICAL					
Medical Surgical Systems	\$ 393,169	\$ 368,911	6.6	4.8	1.8
Diabetes Care	155,104	151,836	2.2	(0.1)	2.2
Pharmaceutical Systems	125,635	101,225	24.1	18.8	5.3
Ophthalmic Systems	14,103	13,020	8.3	4.0	4.3
TOTAL	\$ 688,011	\$ 634,992	8.3	5.8	2.5
BD DIAGNOSTICS					
Preanalytical Systems	\$ 205,128	\$ 183,447	11.8	9.4	2.4
Diagnostic Systems	168,496	163,567	3.0	0.8	2.2
TOTAL	\$ 373,624	\$ 347,014	7.7	5.3	2.4
BD BIOSCIENCES					
Discovery Labware	\$ 48,954	\$ 47,513	3.0	0.4	2.6
Immunocytometry Systems	109,604	100,845	8.7	4.9	3.8
Pharmingen	33,085	31,013	6.7	3.9	2.8
TOTAL	\$ 191,643	\$ 179,371	6.8	3.5	3.3
TOTAL REVENUES	\$1,253,278	\$1,161,377	7.9	5.3	2.6

</TABLE>

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION (FROM CONTINUING OPERATIONS)
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

<S>	United States		
	2004 <C>	2003 (restated) <C>	% Change <C>
BD MEDICAL			
Medical Surgical Systems	\$ 803,529	\$ 759,627	5.8
Diabetes Care	340,669	335,612	1.5
Pharmaceutical Systems	108,027	93,422	15.6
Ophthalmic Systems	22,711	23,296	(2.5)
TOTAL	\$1,274,936	\$1,211,957	5.2
BD DIAGNOSTICS			
Preanalytical Systems	\$ 447,020	\$ 414,270	7.9
Diagnostic Systems	392,137	371,467	5.6
TOTAL	\$ 839,157	\$ 785,737	6.8
BD BIOSCIENCES			
Discovery Labware	\$ 100,821	\$ 97,609	3.3
Immunocytometry Systems	148,741	132,022	12.7

Pharmingen	72,234	68,993	4.7
TOTAL	\$ 321,796	\$ 298,624	7.8
TOTAL UNITED STATES	\$2,435,889	\$2,296,318	6.1

<Page>

Page 10

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION (FROM CONTINUING OPERATIONS)
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	International				
	2004	2003	% Change	FX	FX
	<C>	(restated) <C>	Reported <C>	Neutral <C>	Impact <C>
<S> BD MEDICAL					
Medical Surgical Systems	\$ 737,194	\$ 666,575	10.6	2.6	8.0
Diabetes Care	245,521	206,715	18.8	8.3	10.5
Pharmaceutical Systems	389,394	342,202	13.8	2.7	11.1
Ophthalmic Systems	33,120	29,427	12.5	2.2	10.3
TOTAL	\$1,405,229	\$1,244,919	12.9	3.6	9.3
<S> BD DIAGNOSTICS					
Preanalytical Systems	\$ 340,976	\$ 292,809	16.4	6.5	9.9
Diagnostic Systems	351,506	295,105	19.1	9.6	9.5
TOTAL	\$ 692,482	\$ 587,914	17.8	8.1	9.7
<S> BD BIOSCIENCES					
Discovery Labware	\$ 89,319	\$ 81,814	9.2	(0.4)	9.6
Immunocytometry Systems	248,410	200,364	24.0	14.0	10.0
Pharmingen	63,416	52,180	21.5	10.0	11.5
TOTAL	\$ 401,145	\$ 334,358	20.0	9.9	10.1
TOTAL INTERNATIONAL	\$2,498,856	\$2,167,191	15.3	5.8	9.5

</TABLE>

<Page>

Page 11

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION (FROM CONTINUING OPERATIONS)
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	Total				
	2004	2003	% Change	FX	FX
	<C>	(restated) <C>	Reported <C>	Neutral <C>	Impact <C>
<S> BD MEDICAL					
Medical Surgical Systems	\$1,540,723	\$1,426,202	8.0	4.3	3.7
Diabetes Care	586,190	542,327	8.1	4.1	4.0
Pharmaceutical Systems	497,421	435,624	14.2	5.4	8.8
Ophthalmic Systems	55,831	52,723	5.9	0.1	5.8

TOTAL	\$2,680,165	\$2,456,876	9.1	4.4	4.7
BD DIAGNOSTICS					
Preanalytical Systems	\$ 787,996	\$ 707,079	11.4	7.3	4.1
Diagnostic Systems	743,643	666,572	11.6	7.3	4.3
TOTAL	\$1,531,639	\$1,373,651	11.5	7.3	4.2
BD BIOSCIENCES					
Discovery Labware	\$ 190,140	\$ 179,423	6.0	1.6	4.4
Immunocytometry Systems	397,151	332,386	19.5	13.5	6.0
Pharmingen	135,650	121,173	11.9	7.0	4.9
TOTAL	\$ 722,941	\$ 632,982	14.2	8.9	5.3
TOTAL REVENUES	\$4,934,745	\$4,463,509	10.6	5.9	4.7

</TABLE>

<Page>

Page 12

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

Three Months Ended December 31,
2003 (restated)

<S>	<C>
REVENUES	\$1,185,120
Cost of products sold	634,255
Selling and administrative	324,097
Research and development	58,288
TOTAL OPERATING COSTS AND EXPENSES	1,016,640
OPERATING INCOME	168,480
Interest expense, net	(8,928)
Other (expense) income, net	(911)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	158,641
Income tax provision	33,716
INCOME FROM CONTINUING OPERATIONS	124,925
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAXES OF \$281	477
NET INCOME	\$ 125,402
EARNINGS PER SHARE	
Basic:	
Income from continuing operations	\$0.49
Income from discontinued operations	\$-
Net income	\$0.50
Diluted:	
Income from continuing operations	\$0.48
Income from discontinued operations	\$-
Net income	\$0.48
AVERAGE SHARES OUTSTANDING	
Basic	252,132
Diluted	261,872

</TABLE>

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	Three Months Ended March 31, 2004 (restated)
<S>	<C>
REVENUES	\$1,253,633
Cost of products sold	629,516
Selling and administrative	334,363
Research and development	60,155
TOTAL OPERATING COSTS AND EXPENSES	1,024,034
OPERATING INCOME	229,599
Interest expense, net	(7,960)
Other (expense) income, net	(3,119)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	218,520
Income tax provision	54,437
INCOME FROM CONTINUING OPERATIONS	164,083
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAXES OF \$616	1,077
NET INCOME	\$ 165,160
EARNINGS PER SHARE	
Basic:	
Income from continuing operations	\$0.65
Income from discontinued operations	\$-
Net income	\$0.65
Diluted:	
Income from continuing operations	\$0.62
Income from discontinued operations	\$-
Net income	\$0.62
AVERAGE SHARES OUTSTANDING	
Basic	253,294
Diluted	265,055

</TABLE>

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	Three Months Ended June 30, 2004 (restated)
<S>	<C>
REVENUES	\$1,242,714

Cost of products sold	615,613
Selling and administrative	332,738
Research and development	58,498
Litigation settlement	100,000
TOTAL OPERATING COSTS AND EXPENSES	1,106,849
OPERATING INCOME	135,865
Interest expense, net	(4,127)
Other (expense) income, net	(601)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	131,137
Income tax provision	20,975
INCOME FROM CONTINUING OPERATIONS	110,162
LOSS FROM DISCONTINUED OPERATIONS NET OF INCOME TAXES OF \$509	(766)
NET INCOME	\$ 109,396
EARNINGS PER SHARE	
Basic:	
Income from continuing operations	\$0.43
Loss from discontinued operations	\$-
Net income	\$0.43
Diluted:	
Income from continuing operations	\$0.42
Loss from discontinued operations	\$-
Net income	\$0.41
AVERAGE SHARES OUTSTANDING	
Basic	252,433
Diluted	264,336

</TABLE>